{"id":"W4389480683","doi":"10.1016/j.iotech.2023.100693","title":"LBA3 Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic NSCLC (mNSCLC): 5-year (y) overall survival (OS) update from the POSEIDON study","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Medicine; Internal medicine; Durvalumab; Regimen; Chemotherapy; Gastroenterology; Progression-free survival; Nuclear medicine; Confidence interval; Oncology; Immunotherapy; Pembrolizumab; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001255378,0.0003150501,0.001119243,0.0001642503,0.0001708744,0.0005096843,0.0003566152,0.0002784719,0.001578027],"category_scores_gemma":[0.0003748274,0.0001349875,0.0007868928,0.0002306888,0.0002430963,0.0003210011,0.000192306,0.0009757046,0.0003777112],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005324554,"about_ca_system_score_gemma":0.0005078425,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008838241,"about_ca_topic_score_gemma":0.004103782,"domain_scores_codex":[0.9997926,0.00009551337,0.00001574337,0.00002781072,0.00003014202,0.00003813671],"domain_scores_gemma":[0.9997732,0.00005363866,0.00005836292,0.00001846069,0.00001379087,0.00008251688],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3847532,0.01154543,0.02632907,0.001340739,0.001714422,0.0002097416,0.000243017,0.003051684,0.05329271,0.0004707024,0.007227376,0.509822],"study_design_scores_gemma":[0.2162602,0.5587295,0.164274,0.0002677503,0.003681558,0.001472297,0.0001940245,0.004627146,0.0242611,0.0009715703,0.02516835,0.00009255346],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9886491,0.007974375,0.0003731019,0.0002521055,0.00007408841,0.0002426582,0.0008899636,0.00005303335,0.001491487],"genre_scores_gemma":[0.9918529,0.00401554,0.0007131403,0.0003692955,0.00005560808,0.0002583734,0.001496416,0.00001613236,0.001222648],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001578027,"threshold_uncertainty_score":0.006639183,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02537940517961945,"score_gpt":0.3139009496148696,"score_spread":0.2885215444352501,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}